drugset / Trial / NCT01280682
Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes
RandomizedParallel-groupSingle-blindTreatment
Summary
Transient elimination of B lymphocytes with anti-CD20 monoclonal antibody would decrease immune-mediated destruction of beta cells and result in preserved beta-cell function in patients with type 1 diabetes of recent onset.
Timeline
- Start
- 2010-07
- Primary completion
- 2016-12
- Completion
- 2018-12
Publications
- Ajmal N, Bogart MC, Khan P, Max-Harry IM, Healy AM, Nunemaker CS. Identifying Promising Immunomodulators for Type 1 Diabetes (T1D) and Islet Transplantation. J Diabetes Res. 2024 Dec 20;2024:5151171. doi: 10.1155/jdr/5151171. eCollection 2024.
- Su Z, Ma C, Zhao R, Jiang Y, Cai Y, Yong G, Yang T, Xu X. Heterogeneity of circulating CXCR5-PD-1hiTph cells in patients of type 2 and type 1 diabetes in Chinese population. Acta Diabetol. 2023 Jun;60(6):767-776. doi: 10.1007/s00592-023-02055-6. Epub 2023 Mar 6.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 125 mg/m2 | Other |